|Bid||6.35 x 900|
|Ask||11.34 x 1000|
|Day's Range||10.46 - 11.07|
|52 Week Range||4.11 - 15.50|
|Beta (3Y Monthly)||3.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 86.79% and 153.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.
Arcturus Therapeutics (ARCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
The future of California's stem cell research funding agency is in doubt, but its impact goes far beyond the billions of dollars it has doled out to researchers, says the Glaucoma Research Foundation.
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -54.55% and 25.40%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Every investor in Arcturus Therapeutics Ltd. (NASDAQ:ARCT) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
The direct benefit for Arcturus Therapeutics Ltd (NASDAQ:ARCT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...